DETAIL

18 Aug, 10

DETAIL

Telmisartan is superior to enalapril in providing long term renoprotection in type 2 diabetic patients

Aim

To evaluate the long term renoprotective effect of telmisartan and enalapril in type 2 diabetic patients

Study Patients

Type 2 diabetes and early nephropathy [N=250]

Study Groups

Telmisartan [N=120] vs. enalapril [N=130]

Efficacy Endpoints

Decline rate of glomerular filtration ratio (GFR)

Result

Treatment with Telmisartan for 5 years showed no significant change in GFR when compared to enalapril

Figure 1. Changes from Baseline in the Glomerular Filtration Rate, Based on Analyses of the Last Observation Carried Forward (Panel A) and Complete Five-Year Data (Panel B), According to Treatment Group.

The vertical bars represent the standard deviation.

Change in BP, GFR and urinary albumin excretion rate was similar in both groups.
No differences in changes in serum creatinine

Telmisartan offers renoprotection clinically equivalent to that enalapril in type 2 diabetic patients

N Eng J Med 2004; 351: 1952-61

DETAIL

DETAIL

Aim

Study Patients

Study Groups

Study Duration

Efficacy Endpoints

Result